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Abstract 
Plant extracts contain compounds, which are anti-cancer agents, that possess anti-tumour 
activity. Most of these compounds are known to hinder the activation of cell cycle and induce 
cell death. During various types of stress in a normal cell, p53 and Rb enhance programmed cell 
death to prevent human tumour cells from forming.  However, programmed cell death is not 
enhanced in the presence of RBBp6 or Mdm2. Thus, cell cycle will be enhanced, resulting to 
abnormal cells proliferating and causing cancerous cells or tumours. RBBp6 is a p53-associated 
cellular protein and retinoblastoma binding protein containing a conserved N-terminal ring-
finger domain, which takes part in p53 degradation. RBBp6 is highly expressed in lung cancer 
and may be a promising target for treating cancer. The aim is to use plant extracts to regulate the 
expression of RBBp6, switching it off from being pro-carcinogenic to becoming an anti-
carcinogenic protein in lung cancer cells. Two cancer cell lines (Lsqr1 and A549) were cultured 
and treated with Euphorbia mauritanica and Kedrostis hirtella extracts. A MTT assay was used 
to determine 50% cell death, which was induced by 5 μg/ml and 10 μg/ml of the Euphorbia 
mauritanica and Kedrostis hirtella extracts after 22 hrs and 24 hrs, respectively. Molecular 
analysis using gel DNA fragmentation showed smeared DNA due to necrosis and a fragmented 
DNA induced by apoptosis.  The quantity of cells undergoing apoptosis and necrosis was 
measured by flow cytometry, which showed a higher percentage of necrotic cells compared to 
apoptotic cells. Real-time PCR was used in order to analyse the RBBp6 expression in lung 
cancer cells treated with the plant extract. The results of the present study showed no change or 
an insignificant decreased in the expression of RBBp6 in lung cancer cells treated with the 
extracts. Therefore, plant extracts used in this research have no effect on RBBp6 as anti-cancer 
therapy. 
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Chapter 1 
1 Introduction 
1.1 Overview of cancer 
Cancer is a public health problem in the world. Diagnoses based on the updated incidences, 
mortality, new cancer cases and survival rate show that the major problem is in economically 
developing countries (low and medium resource countries) (Parkin et al, 1993). This global shift 
is influenced by factors such as genetic instability (pre-existing disease and family history of a 
cancer syndrome), chronic infections and entrenchment of modifiable risk factors, for example, 
environmental pollutants such as carcinogens from smoking (Parkin et al, 1993; Pauk et al., 
2005). 
  
Smoking is a central pollutant that increases the progression of cancer more rapidly.  It 
commonly affects the population age of 20-65 year olds in both smokers and non-smokers. 
Exposure to tobacco smoke may increase the risk of lung cancer causing over 500000 deaths 
each year (Massion and Carbone, 2003; Bradshaw et al., 2003).  Moreover, smoking can partly 
contribute to other types of cancer such as oral cavity, oesophagus, stomach, kidney and acute 
myeloid leukaemia. These cancers account for 1.4 million cancer deaths that occur worldwide 
especially in developing countries of which one-fifth is estimated to be lung cancer (Parkin et al, 
1993; Pisani et al., 1999; Pauk et al., 2005).  
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1.2 Lung cancer 
Lung cancer has been a common cancer in the world that is often connected to smoking (Parkin 
et al., 1993; Pisani et al., 1999; Zang et al., 2000; Ries et al., 2005). Lung cancer is divided into 
two types: the small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).  
 
1.2.1 Small cell lung cancer 
Small cell lung cancer is a highly malignant, aggressive neoplasmic form of lung cancer, which 
has the ability to form central endobronchial lesions in chronic cigarette smokers (Fong et al., 
2003). It is frequently associated with distant metastates and has the poorest prognosis of all lung 
cancers. It can be subdivided into three types; namely, the small cell carcinoma (oat cell cancer), 
intermediate cell type and combined small cell carcinoma, which are capable of multiplying and 
spreading rapidly (Girard et al., 2000). Small cell lung cancer cells normally lose alleles in 
chromosomes, triggering the early stage of lung cancer (Motadi et al., 2007).  
 
1.2.2 Non-small cell lung cancer 
Non-small cell lung cancer is categorised into squamous cell carcinoma, adenocarcinoma and 
large cell carcinoma. Large cell carcinoma and adenocarcinoma tumours arise from damaged 
epithelial tissues and are transformed into cancer cells (Terasaki et al., 2003; Motadi et al., 
2007). Squamous cell carcinoma grows on the epithelial surface of a bronchus resulting in 
uncontrolled multiplication of malignant cells  (Franklin et al., 2003). Squamous cell carcinoma 
accounts for 30% of lung cancer in men compared to women . Squamous cell tumours and large 
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cell carcinoma tumours are also associated with smoking and exposure to arsenic (Pauk et al., 
2005).  
 
Adenocarcinoma is responsible for 40% of lung cancer occurrence in women and often affects 
non-smokers. The chance of getting adenocarcinoma depends on how frequently one smokes.  
Other secondary risk factors that may lead to this type of lung cancer are age, family history, and 
being passive smoker, mineral and metal dust, asbestos and radon. Hence, adenocarcinoma is the 
most common lung cancer. Adenocarcinoma lung cancer grows slowly and its symptoms 
develop slowly. The symptoms are vaguely diagnosed by coughing, shortness of breath, 
wheezing, chest pain, and bloody sputum (Fauquier et al., 2003) 
 
1.2.3 The cause of genetic mutation leading to lung cancer  
Carcinogens of tobacco smoke have a benzo (a)-pyrene diol epoxide that causes genetic lesions 
in the respiratory epithelium. Genetic lesions lead to several chromosomal abnormalities and 
structural cytogenetic abnormalities (Hecht, 1999; Massion and Carbone, 2003; Bradshaw et al., 
2003; Pauk et al., 2005). About 85% of mutations are due to chromosomal and structural 
cytogenetic abnormalities, which are enhanced by carcinogens. Carcinogens covalently bind to 
deoxyribonucleic acid (DNA), forming a DNA adduct that causes severe genetic mutations, 
which lead to defective structure and function of tumour suppressor proteins (p53 and Rb) 
involved in apoptosis and cell cycle (Wang et al, 2003; Wang et al, 2004; Weinstein and Joe, 
2006).  
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The most commonly seen adduct formation occurs at the codon 157 hot spot of p53. The 
mutation pattern is the GT transitions resulting from DNA 5-methylcytosine binding on the 
tobacco carcinogens at the CpG dinucleotide (Dennissenko et al., 1997; Lewis and Perry, 2004). 
This mutation pattern leads to a dysfunctional p53, which fails to delay or terminate the cell 
cycle when the DNA is damaged. Failure to terminate the cell cycle in such a case results in 
growth advantages of progressive and invasive cells that might lead to cancer (Evan and 
Vousden, 2001; Lowe et al., 1993; Wang, et al, 2003; Hemann and Narita, 2007). 
 
1.3 Tumour suppressor proteins involved in apoptosis and cell cycle 
1.3.1 p53  
 
 
 
 
 
Figure 1:1 Ribbon representation of p53 tumour suppressor protein. The structure was generated 
using Swiss-pdb viewer (Perez-Canadillas et al., 2006). The PDB code used to generate this 
structure is 2FEJ. 
 
Central DNA-binding 
core domain 
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p53 is a nuclear phosphoprotein and genes encoding for this protein are found at the short arm of 
chromosome 17. It consists of 393 amino acids with a molecular weight of ~53 kDa (Lane et al., 
1979; Levine et al., 1997).  It is is a tetramer protein, with identical subunits.  Each subunit 
contains seven domains. It contains a nuclear localization signaling domain, a DNA-binding core 
domain (p53DBD) which is essential for binding the p53 co-repressor. The N-terminal 
transcription domain activates transcription factors. It has an activation domain, which is 
important for apoptotic activity, and a tetramerization domain essential for the activity of p53 in 
vivo. C-terminal regulatory domain is involved in the down-regulation of DNA binding of the 
central domain. However, the main focus of the p53 structure (Figure 1:1) is on the DNA-
binding core domain (p53DBD) (Ho et al., 2006; Perez-Canadillas et al., 2006) 
 
1.3.2 Retinoblastoma (Rb1) 
pRb is a pocket protein, genes encoding for pRB are  located in human chromosome 13 and 
codes for a 110 kDa nuclear phosphoprotein. pRb is an important tumour suppressor protein for 
controlling the G1 progression point and is involved at the first checkpoint of G1/S metaphase, 
before the cell enters S phase for DNA replication. It regulates the cell cycle by interacting with 
G1 cyclin and cyclin dependent kinases (Nigg, 1995; Taya, 1997).   
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Figure 1:2 The dissociation of RB-E2F complex enhanced by kinase complex (Cdk-Cyc) which 
hypophosphorylates Rb, thus, promoting the release of E2F transcription factor resulting to cell 
progression. 
 
pRB-E2F complex in Figure 1:2 promotes regulated cell growth or apoptosis (Hickman et al., 
2002). (Figure 1:2) Rb is hypophosphorylated by kinase complex (Cdk-Cyc) at the Cdk 
consensus sites and dissociates Rb-E2F interactions. Hypophosphorylated Rb promotes cell 
progression to S-phase with activation and release of E2F transcription factor (Harbour et al., 
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1999; Harbour and Dean, 2000) (Figure 1:2). When E2F transcription factor is functionally 
active, it will improve expressing transcriptional genes necessary for cellular replication 
functions during the S phase (Harbour and Dean, 2000). The cell will progress from G1 into the S 
phase, and then cell division will occur at the S phase if cells are normal (Figure 1:2). Once cells 
have divided, Rb becomes dephosphorylated and begins to associates with E2F; this suppresses 
the G1 to S phase transition. Hence, it prevents the cell from passing through the starting point of 
G1 to S-phase by shutting off the transcription of genes needed for cell division (Harbour et al., 
1999; Harbour and Dean, 2000; DeGregori, 2005).  Therefore, when the Rb gene has missing 
functional copies, it results in a mutant Rb gene product which is always phosphorylated and 
cannot be regulated by E2F. Thus, the control of cell division at the S phase does not occur and 
normal cells become cancerous (Harbour et al., 1999; Harbour and Dean, 2000; Mani et al., 
2000).  
 
1.4 Cell cycle 
Cell cycle is an important mechanism in the cell; it controls the normal cell from becoming 
cancerous by either proceeding to the next stage of cell division or induces apoptosis (Smith and 
Martin, 1973; Garrett, 2001). Cell cycle is strictly controlled from one phase to the next, and 
these are called checkpoints. Checkpoints can be considered as safety measures for the normal 
cell cycle by preventing the cell from entering another cycle before any damages are properly 
repaired and these depend on the production of tumour suppressor proteins such as p53 and Rb 
(Figure 1:3).  
 
8 
 
 
 
 
 
 
 
 
     
        
                                                                                                                                                          
 
 
Figure 1:3 Cell cycle diagram showing different phases of which  p53 functions to check and 
repair the damaged DNA at all check points and pRb activity is at the restriction point (R). 
Activation is indicated with      and inhibition (      ). The S-phase is the synthesis phase, mitotic 
(M-phase), G2 interphase, before the S-phase and G2 is the interphase after the S-phase. The 
diagram was modified from Grana and Reddy (1995). 
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1.5 Apoptosis pathway  
Pathological ways, which reduce tumour cells during intense stressful abnormal growth lead to 
apoptosis or programmed cell death. The suicide of tumour cells can be approached by the use of 
different drugs that affect genes, which mediate apoptosis (Kerr et al., 1972). However, damage 
to DNA or to other critical molecules can stimulate some inducers, which respond to the cellular 
stress. These inducers may have an intense impact on apoptosis pathway (Debatin, 1997; 
Kaufmann and Earnshaw, 2000; Herr and Debatin, 2001; Rich et al., 2000). 
   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1:4 p53 as a mediator in Cell cycle and apoptosis pathway. The pink arrows represent cell 
cycle, and this is occurs when the DNA is repair. However, should the DNA fail to be repair cell 
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death will be induced this is indicated by the purple arrows. Activation of p21 will induce cell 
death as well as inhibit (     ) cell cycle. 
 
Figure 1:4 shows that stress signals or damaged DNA activates the build-up of p53 and a 
transcriptional expression of genes that are involved in cell cycle arrest or apoptosis (Figure 1:4). 
p53 is one of the inducers that induces intrinsic apoptosis pathways and it does so by acting as a 
receiver of stress signals that include damaged DNA. It is involved in multiple stress signals of a 
diverse antiproliferative series of responses (Rodin and Rodin, 2000; Hickman et al., 2002, 
Hussein et al., 2003). When p53 is functional, it repairs damaged DNA through the activation of 
p21 thus result in caspase activation which will induce intrinsic apoptosis (Levine et al., 1997; 
Wu et al., 2004). If damaged DNA fails to be repaired, pRb induces apoptosis by binding to E2F 
to form a complex that inhibits cell cycle, promoting cell death.  
 
Ineffective DNA repair (Figure 1:3 and Figure 1:4) results to p53 activating p21, cdk2 inhibitors. 
These will regulate cell cycle event by stopping cell progression at G1/S and G2/M phases and 
apoptosis will take place (Garrett, 2001; Hussein et al., 2002). Defective p53 abolishes its 
capacity to activate p21 reporter (Levine et al., 1997; Czajkowski et al., 2002). In so doing, it 
prevents an intrinsic apoptosis pathway from occurring by enhancing the cell cycle of 
unsuccessful checkpoints and the completion of mitosis. Therefore, aberrant daughter cells will 
be produced resulting in uncontrolled growth (Hartwell & Weinert, 1989; Lowe et al., 1993; 
Stephen, 1996), altering other genes (p16, p14) involved in the Rb and p53 pathways (Murakami 
et al., 1991; Lowe et al., 1993; Hickman et al., 2002). 
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1.5.1 RBBp6 (A p53 and Rb binding protein) 
RBBp6 (Retinoblastoma binding protein 6) is a 250 kDa splicing-associated protein found in 
eukaryotes (Simon et al., 1997). It is usually expressed in heart, lung, liver skeletal muscle and 
testes (Witte and Scot, 1997). 
  
 
 
 
 
Figure 1:5 The structure of the RBBP6 proteins. The  diagram is modified from Pugh et al. 
(2006) 
 
Figure 1:5 shows that RBBp6 is a multi-domain protein made up of the DWNN domain, a zinc 
knuckle and a ring-finger domain. Highly conserved RBBp6 N-terminal has the DWNN domain 
and ring-finger domain.  RBBp6 can also interact with 19 multifunctional Protein YB-1 through 
its ring-finger domain resulting in the ubiquitination of YB-1 and proteosomal degradation in the 
proteosome (Sakai et al., 1995; Mather et al., 2005). The DWNN domain has an ubiquitin-like 
fold which regulates pre-mRNA processing protein (Mather et al. 2005; Pugh et al., 2006). 
Humans RBBp6 has C-terminal extension containing p53 and Rb-interaction domains. p53 
binding domain interacts with p53 and suppresses the binding of p53 to DNA. The Rb domain 
binds to Rb and blocks the binding of E2F transcription factors (Figure 1:5) (Yoshitake et al., 
2004; Pugh et al., 2006).  
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p53 has an excision repair system which is crucial for maintaining the genome integrity. RBBp6 
protein associates with p53-cellular protein and stimulates ubiquination and degradation of p53. 
This will interfere with p53 binding to damaged DNA. As a result apoptosis will be inhibited 
(Wang et al., 2003). However, cell proliferation will be enhanced because Rb is prevented from 
binding to the transcription factors. Thus, in the presence of the functionally active transcription 
factors, expression transcriptional genes are necessary for cellular replication functions, and the 
cells with damaged DNA will replicate abnormally (Sakai et al., 1995; Mather et al., 2005).  
 
Moreover, Li et al., 2007 report that RBBp6 does not itself ubiquinate p53. Speculation says that 
it may play a role in scaffolding on the interactions that take place between p53 and Mdm2, and 
promote p53 degradation by enhancing the Mdm2 activity (Li et al., 2007). Mdm2 has a highly 
conserved ring-finger domain which is similar to that of RBBp6, and has a similar function by 
interacting with tumour suppressor protein identified as p53 and Rb. In doing so, Mdm2 
promotes cell cycle progression on normal cells, thus preventing these cells from programmed 
cell death. However, should cells be cancerous, Mdm2 still performs its function by preventing 
cell death and advancing cell cycle progression. Hence, most cancer cells have overexpression of 
Mdm2 and RBBp6 protein (Jones et al., 1995, Luna et al., 1995).   
 
To prevent cancer, research was done to produce inhibitors that prevent p53 from interacting 
with Mdm2 (Justin and Murray, 2007), whereas others focused on creating anti-sense 
oligonucleatides that inhibit expression of Mdm2. Other ways were to alter the genes of this 
protein by alternative splicing and produce a spliced variant such as Mdm2b isoform, which has 
eight exons missing resulting in a structure without a p53-binding domain.  For that reason, it is 
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clear that research done on Mdm2 was of benefit to inhibit Mdm2 from enhancing cancer cells 
(Wang et al., 2004).  
 
1.6 Plant extracts as anti-cancer agents 
Plant secondary metabolites are the source of pharmaceutical drugs and many medicinal 
derivatives (Harvey, 1999; van Wyk et al., 1997). Over the years, the system of drug discovery 
have developed useful chemotherapeutic drugs for various types of cancer, which are successful 
in most human cancer treatment, but do not guarantee long-life span. Tumours in adults have 
shown resistance to some antineoplastic drugs because they have a limited anti-solid tumour 
activity (Harvey, 1999; Mans et al., 2000; Mann, 2002). Moreover, inadequacy of current 
chemotherapeutic agents for the treatment of advanced solid malignancies led to consideration of 
traditional drugs as anti-cancer agents, thus, improving their efficiency by critically assessing 
discovery methodologies of using plant-derived compounds for cancer therapy (Chabner, 1991; 
Harvey, 1999).  
 
Traditional medicines derived from plant sources have been used as anti-cancer agents from the 
1950s and were discovered in tropical and sub-tropical regions of the world. During 1960-1982, 
about 3500 plant samples were tested against leukemia cell lines. In 1985, the NCI (National 
Cancer Institute) started a new programme using plant extracts to test against human cancer cell 
lines. Recently, about 60% of anti-cancer drugs have been derived from natural sources such as 
plant extracts (Cragg and Newman, 2000; Mann, 2002; Newman et al., 2000; Newman et al., 
2002).  The extracts of plant species contain compounds which are anti-cancer agents that 
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possess anti-tumour activity. The mechanism of action of these anti-cancer agents from plant 
extracts remains unclear. However, the structure and mechanism of action of some anti-cancer 
agents have been elucidated and are used as drugs in chemotherapy (Nair et al., 1991; Perry, 
1992; Salomi et al., 1992). The first anti-cancer agents to be used clinically were vinblastine and 
vincristine isolated from Catharanthus roseus. Vinblastine and vincristine isolate were used to 
test for cytotoxicity activity against cancer cell lines and normal tissue grown either in vitro or 
used in vivo models. Vinblastine and vincristine inhibits mitosis (cell division) in metaphase by 
preventing the cell from moving its chromosomes around as it divides; vinblastine also interferes 
with glutamic acid metabolism in order to fight cancer. Thus, vinblastine is useful against 
advanced testicular cancer, breast cancer, Kaposi's sarcoma and leukemia (Stokoe et al., 2001; 
Groninger et al., 2005).  
 
Moreover, studies done by Wirger et al., (2005) reveal that the flavopiridol compound isolated 
from leaves or stems of Amoora rohituka inhibit 50% proliferation in bladder cancer cells when 
used as cytotoxicity anti-cancer agents. Flavopiridol is involved in the mechanism of cyclin-
dependent kinases by hindering activation and blocking cell cycle progression at G1 or G2 
(Killand, 2000; Wirger et al., 2005). Etoposide is an epipodophyllotoxin, derived from the 
mandrake plant Podophyllum peltatum and the wild chervil Podophyllum emodi also has 
significant activity against small-cell lung carcinoma (StÄhelin et al, 1973). Therefore, plant 
extracts have significant impact by interacting with genes that trigger cell death and control cell 
cycling in cancer cells. Hence, plant extracts were used in this research to target specific genes in 
lung cancer cells that might induce cell death.  
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Plant extracts used for this research were Euphorbia mauritanica and Kedrosis Hirtella. 
Euphorbia mauritanica is a spineless succulent bush plant. It’s found in the Northern Cape, 
Western Cape Eastern Cape Kwazulu Natal and Free state. It is known to cause diarrhoea, fever 
and fatal disorder in sheep (Mitch, 1984) yet traditional healers use it to treat cancer. Kedrostis 
hirtella is green, and has velvet leaves and stem. It is found in Gauteng and Western Cape. The 
roots of this plant are used to make beer for tswana people but it fruit is posionus. Plant is also 
used for medicinal purpose in Transkei and has fatal poison (Watt and Beyer-Brandwijk, 1962; 
Van Wyk and Gericke, 2000). Although these plants are poisonous, traditional healers boil the 
leaves and roots and use the extracts to treat cancer. When boiling the plant some compounds 
become inactive and this might be the poisonous or harmful compounds. Therefore this study 
will prove whether the plant extracts are useful as cancer treatment.    
  
1.7 Aim 
The main aim of this research was to test for anti-cancer activity on RBBp6, when lung cancer 
cells are treated with Euphorbia mauritanica and Kedrostis hirtella extracts. 
 
1.7.1 Objectives 
To achieve the main Aim, the objectives were as follows: 
o Determine whether lung cancer cells treated with Staurosporine, extracts of Euphorbia 
mauritanica and Kedrostis hirtella reach a net saturation level of 50% cell death 
o Determine the percentages of viable cells, cells undergoing apoptosis and necrosis in cells 
treated with Staurosporine, extracts of Euphorbia mauritanica and Kedrostis hirtella 
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o Determine the expression level of RBBp6 and p53 in cells treated with Staurosporine, 
extracts of Euphorbia mauritanica and Kedrostis hirtella. 
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Chapter 2 
2 Materials and Methods 
2.1 Materials 
The following reagents used were obtained from Sigma-Aldrich (USA):  10 mg/ml penicillin, 10 
mg/ml streptomycin, trypsin; DMEM, FBS, 0.1 M phosphate buffered solution (pH 6.0), MTT, 
DMSO, Magnesuim chloride and SYBr green. RNA extraction kit, DNA ladder and the DNA 
loading dye were purchased from Fermentas (South Africa). The reverse transcriptase kit was 
obtained from Promega (South Africa). Proteinase K, SDS, phenol, chloroform, sodium acetate, 
100% isopropanol, alcohol, Tris-borate, EDTA and agarose powder and ethidium bromide are 
products from Merck (South Africa). Annexin-V-FITC dye was purchase from Abcam. Primers 
were synthesised by Inqaba biotech (Pretoria, South Africa).  
 
2.1.1 Ethics Approval 
The University of the Witwatersrand Human Ethics Committee was applied to for an ethic 
clearance and it was granted. 
  
2.1.2 Cancer cell lines 
Normal primary human fibroblasts, A549 and Lqr1 cell lines were purchased from the Japan 
Health foundation.  Normal primary human fibroblasts have structural framework (stroma) for 
animal tissues and they synthesize the extracellular matrix and collagen. A549 cells are 
adenocarcinomic human alveolar basal epithelial cells . Lsqr1 are squamous cell carcinoma and 
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theygrow on the epithelial surface of a bronchus resulting in uncontrolled multiplication 
of malignant cells. A549 and Lsqr1 grow as monolayer cells adhering or attaching to the culture 
flask when cultured in vitro.  
2.2 Methods 
2.2.1 Preparation of aqueous extracts 
Fresh South African plants, roots and leaves (Euphorbia mauritanica and Kedrostis hirtella) 
were thoroughly washed with distilled water, and dried in a ventilation oven for 72 hrs at 35 °C. 
Dried leaves were ground to a fine powder and 10 g of powder was extracted in 1 litre of boiling 
water and allowed to cool prior to centrifugation at 1000 × g. Extracts of boiled leaves were 
passed through a 850 μm pore sieve to obtain the supernatant. Stocks of 40 mg/ml were freshly 
prepared and stored at −20 °C until needed.  
 
2.2.2 Cell culturing  
Two human lung cancer cell lines A549 (Adenocarcinoma) and Lsqr1 (Lung squamous) were 
used to carry out the plant extracts trial research work. Cells were thawed in a 37 ºC water bath 
and centrifuged for 2 min. The supernatant was discarded, and the pellet was resuspended in a 
tissue-culturing flask containing Dulbecco’s minimum essential media (DMEM) supplemented 
with 10% Fetal Calf Serum (FCS) for medium growth and 1% pen/strep to prevent 
contamination. The cultured cell lines were grown at 37 °C in a humidified atmosphere of 5% 
(v/v) CO2 until they were confluent. Adherent confluent cells were washed three times with PBS 
and trypsinised for 2 min to detach them from the surface of the flask.  After cells had detached, 
15 ml DMEM (supplemented with 10% FCS and 1% pen/strep) was added into the flask and the 
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flask was gently shaken to distribute media evenly, resuspend detached cells and deactivate 
trypsin. Cells were resuspended into a 15 ml tube, centrifuged at 3000 x g for 4 min and the 
supernatant was discarded. Cells were either supplemented into three flasks containing DMEM 
(supplemented with 10% FCS and 1% pen/strep) or frozen into cryovia. The process of freezing 
cells was as follows: cells were suspended in enough freezing media (DMEM containing 20% 
FCS and 10% DMSO) and pipetted up and down to ensure even mixture, followed by liquoring 
of 1 ml into storage vials. Vials were immediately kept in cotton wool and transferred to -70 °C.   
 
2.2.3 Preparing cells (A549 and Lsqr 1) for treatment with plant extracts 
Before conducting any experiment, cells were grown in a culture flask until they were confluent. 
Confluent cells were washed three times with PBS and trypsinised for 2 min in order for them to 
detach. After cells had detached, 10 ml DMEM (supplemented with 10% FCS and 1% pen/strep) 
was added in a cultured flask. Cells were seeded in a 96-well tissue culture plate at a 
concentration of 2.5x10
4
 cells per well and incubated at 37 °C overnight. Thereafter, cells were 
ready for testing with plant extracts and Staurosporine. Staurosporine was used as a positive 
control as it induces the desired cytotoxicity. Staurosporine has derivatives with an ability to 
block the cell cycle of cancer cells, but have a reversible protective effect of G1 arrest on normal 
cells, which makes these potent agents in cancer treatment (Lin et al., 1999; Gescher et al., 1998; 
Bunch et al., 1996, Chen et al.,1999; Mack et al., 1999). 
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2.2.4 Cell cytotoxicity and viability assay 
Cell cytotoxicity and viability assays measure cell death and the viability of untreated or treated 
cells. The assay measures the activity of enzymes that reduce MTT to formazan dyes resulting in 
a purple colour that allow cells to be recovered if desired. The MTT dye has tetrazolium salt 
which is used as a quantitative assessor for mammalian cell survival and proliferation. It detects 
living cells according to the degree of the signal generated in activated cells (Mossman, 1983). 
MTT can also be used to determine anti-tumour activity or cytotoxicity of potential anti-cancer 
drugs, which stimulate or inhibit cell viability and growth. Thus, the assay examines drug 
sensitivity profiles for patients with hematological malignancies and screen potential 
chemotherapeutic drugs (Alley et al., 1982; Mossman, 1983). However, the assay does not 
measure dead cells because they are unable to reduce MTT within 30 min of lysis (Mossman, 
1983).  
 
Moreover, the MTT assay has high degree of precision because there is no washing step after 
adding MTT dye. MTT dye has a tetrazolium ring, which is cleaved by mitochondrial 
dehydrogenases of viable cells.  Cleaving the tetrazolium ring forms purple MTT formazan 
crystals that are insoluble in an aqueous solution, but dissolved in acidified isopropanol or 
DMSO. When DMSO is added, it solubilises formazan crystals into a purple colour; this can be 
used to detect viable cells spectrophotometrically at 570 nm. In order to prepare for the 
experiment, MTT solution (1 mg/ml in PBS) was prepared, filtered through a 0.2 µm sterile 
filter.    
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Cells were seeded in five 96-well plates for treatment with the extracts (Euphorbia mauritanica 
and Kedrostis hirtella) and 25 nM Staurosporine. They were incubated overnight at 37 
o
C to 
allow them to adhere to the surface. Thereafter, seeded cells were divided in triplicates of 
untreated cells (negative control) and cells treated with 5 µg or 10 µg of plant extracts 
(Euphorbia mauritanica and Kedrostis hirtella) and 25 nM Staurosporine. Wells without cells 
were used as blank.  Five cultured plates containing treated and untreated cells were incubated 
for 4 hrs, 8 hrs, 16 hrs, 22 hrs and 24 hrs at 37 
o
C, respectively. After each time interval, the 
media were discarded and 10 µl MTT plus 90 µl of DMEM were added into each well, including 
the cell-free (blank) wells. Plates were incubated for 4 hrs at 37 °C with 5% CO2. After 
incubation, MTT formed formazan crystals of viable cells. The MTT solution with DMEM was 
removed and 100 µl of DMSO or isopropanol was added to solubilise the formazan crystals. The 
plates were further incubated for 5 min at room temperature and the optical density (OD) of the 
wells was determined using a plate reader. The plate reader used a light wavelength of 570 nm 
and subtracted background absorbance measured at 690 nm. Percentage cytotoxicity was 
calculated as follows:  
  
                             
 
2.2.5  DNA fragmentation gel electrophoresis 
Biochemical properties of cell death induced by a variety of agents may result in apoptosis or 
necrosis. A necrotic cell has a physical injury of the cell membrane ensuing from cell swelling 
due to the influx of water and sodium ions (Kroemer et al., 1997). Influx of water and sodium 
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ions is caused by loss of regulation of ion homeostasis, which results from a passive process with 
no energy requirement.  An important distinction between necrosis and apoptosis is the facts that 
cells that have undergone apoptosis, form apoptotic vesicles that are phagocytosed by 
macrophages or neighboring cells preventing inflammation, whereas necrotic cells result in 
inflammation (Ren and Savill, 1998; Studzinski, 1999). In 1980, Wyllie A. reported apoptotic 
cells to have degraded nuclear DNA that is cleaved into internucleosomal DNA pattern.  
 
DNA fragmentation is a characteristic of apoptosis, though the biological function of apoptotic 
DNA fragmentation is unclear. Nonetheless, it is speculated that during apoptosis specific DNase 
such as caspase-activated DNase (CAD) cleaves chromosomal DNA in a caspase-dependent 
manner (Glucksmann, 1951; Williason, 1970; Wyllie, 1980; Nagata, 2000). CAD attacks 
chromatin to yield 3-hydroxyl and 5-phosphate, creating 50- to 300-kb cleavage products which 
are oligonucleosomal fragmentation. Cancer cells, however, have DFF45 existing as a 
heterodimer in the nucleus. DFF45 is often called an inhibitor of CAD (ICAD). It is a 45-kDa 
chaperone, which has an inhibitory subunit (Widlak et al.,2005).  
 
CAD is synthesised with the assistance of ICAD (inhibitor of CAD) working as a specific 
chaperone for CAD. CAD often forms a complex with ICAD, which will result in proliferating 
cells. However, dissociation between CAD:ICAD complex cells will enhance apoptosis 
(Williams et al.,1974). Thus, the aim of this experiment is to see if there is proliferation, necrosis 
or fragmentation in treated and untreated lung cancer cells.   
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2.2.5.1 DNA Fragmentation Assays for Apoptosis Protocol 
 DNA was extracted from treated and untreated A549 and Lsqr1 cell lines. The A549 cell line 
were treated for 22 hrs while the Lsqr1 cell line were treated for 24 hrs with 5 µg and 10 µg of 
plant extracts (Euphorbia mauritanica and Kedrostis hirtella), respectively, and 25 nM 
Staurosporine. The cells were harvested into a sterile 15 ml tube and centrifuged for 10 min at 10 
°C (1200 x g). The supernatant was discarded and the cell pellet was resuspended in 1X PBS.  
The pellet was washed twice with 10 ml 1X PBS and centrifuged between the washes. The pellet 
was resuspended in 10 ml DNA buffer and centrifuged for 10 min at 10 °C (1200 x g) to remove 
the supernatant. DNA buffer (3 ml), 125 µl of Proteinase K and 400 µl of SDS were added to the 
pellet and gently shaken, then incubated overnight at 45 °C. After incubation, 36 µl of phenol 
was added and the tube was shaken for 10 min at room temperature and centrifuged for 10 min at 
10 °C (3000 x g).   
 
The supernatant was transferred into a new tube and 1.8 ml of phenol and chloroform were 
added. The solution was shaken by hand at room temperature and centrifuged for 10 min at 
10 °C (3000 x g). The supernatant was transferred into a new tube; 1000 µl of sodium acetate 
buffer (pH 5.2) and 100% isopropanol were added and shaken until DNA precipitated. The 
precipitated DNA was transferred into a tube and washed with 5 ml alcohol. DNA was 
transferred into a sterile eppendorf tube, spin down, decant, and resuspend the precipitates in 
20ul of deionized water-RNase solution (0.4ml water + 5ul of RNase) and 5ul of loading buffer 
for 30 minutes at 37°C. Also insert 2ul of Hindi III marker (12ul of Stock IV) on the outer lanes. 
Run the 1.2% gel at 5V for 5min before increasing to 100 V.  Gel electrophoresis was used as a 
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visualisation technique, to investigate whether extracted DNA of treated or untreated cells are 
either fragmented, smeared or had a single band.  
  
2.2.6 APOpercentageTM assay (Ascertaining whether cytotoxicity is induced by apoptosis 
or necrosis)  
Flow cytometry was used to quantify apoptosis. It is a rapid, quantitative measurement of 
apoptotic cells. During apoptosis the cells shrink, resulting in the condensation of chromatin and 
DNA fragments because of endonuclease. Flow cytometry is used to measure apoptotic changes 
in cells by staining them with various DNA dyes (Darzynkiewiez et al., 1992). The majority of 
staining methods are used on unfixed cells because of the fragility of cells undergoing 
programmed cell death and the importance of maintaining the cells in their natural state for 
reliable results (Dive and Hickman, 1991; Gougeon et al., 1992; Ormerod et al., 1992; Schmid et 
al., 1994). 
  
The APOpercentage™ detection assay is used to measure the occurrence of apoptosis and 
necrosis during a vitro culture. Annexin-V-FITC dye is used to select cells that are 
predominantly undergoing apoptosis. During apoptosis, phosphatidylserine (PS) is translocated 
from the cytoplasmics face of the plasma membrane to the cell surface. Annexin-V-FITC binds 
to the phosphatidylserine residue that appears on the surface of a cell as an early indication or 
parameter of apoptosis. Annexin-V-FITC has a strong Ca
2+
- dependent affinity for PS. It can be 
used as a probe for detecting apoptosis by analyses of flow cytometry (Gougen, 1997).  
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Flow cytometry has staining methods that uses Annexin-V for detecting phosphatidylserine, 
which serves as a marker of apoptosis on the cell surface. During early apoptosis, the cell 
morphology changes, expressing phospatidylserine on the outer cell membrane. The expressed 
phospatidylserine binds to Annexin-V at the early stage of apoptosis and is used as a probe for 
detecting apoptosis (Vermes et al., 1995). For further analysis of cell cycle and late 
apoptosis/necrosis was detected with propidium which is a fluorescent dye that binds to the 
DNA.  When excited by 488nm laser light, it can be detected with 562-588nm band pass filter.    
 
Propidium iodide or 7-amino-actinomycin D stain is added to discriminate dyed dead cells that 
are at late apoptosis or the necrosis stage, distinguishing them from early apoptotic cells (Vermes 
et al., 1995; Telford et al., 1992).  However, viable cells have normal cell membrane 
phospholipid symmetry, which is why they will not bind to Annexin-V-FITC and propidium 
iodide.  Therefore, necrotic, viable cells and apoptotic cells can be classified on the basis of a 
double labelling of annex V and PI analysed by flow cytometry (Ormerod, 1992; Schmid, 1994; 
Lecoeur and Gougen, 1997). 
 
Cells seeded in a 48-well tissue culture plate were treated with plant extracts (24 wells), and 
Staurosporine (12 wells), and other wells (12 wells) contained untreated cells. Wells were 
washed three times with 1 ml PBS to remove plant extracts (Euphorbia mauritanica and 
Kedrostis hirtella) and Staurosporine. Cells were then detached from the surface with 10 μl 
trypsin in each well. Detached cells were aliquoted into four 15 ml centrifuged tubes 
(Staurosporine, plant extracts (Euphorbia mauritanica and Kedrostis hirtella) and untreated 
cells). Each tube was centrifuged at 500 × g for 5 min and the remaining media were discarded. 
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Cells were resuspended in 500 μl of 1× binding buffer, and then 5 μl of Annexin-V-FITC and 5 
μl of propidium iodide were added. Samples were incubated for 15 min in a dark place at room 
temperature. Each sample was analysed using flow cytometry (FASCan instrument equipped 
with Ex= 488 nm and Em = 530 nm argon laser as a light source was used to analyse the 
samples). The Annexin-V-FITC binding was measured using FITC signal detector (FL1 channel) 
and PI staining by a phycoerythrin signal detector (FL2 channel).  
 
2.2.7 Total ribonucleic acid (RNA) extraction 
RNA was extracted from three different flasks that had either transfected cells, treated cells or 
untreated cells. Each flask was washed three times with PBS and 800 µl of trypsin was added 
and incubated (room temperature) for 2 min in order for cells to detach. The cells were 
resuspended in 500 µl PBS and transferred into sterile 1.5 ml centrifuge tubes. Samples were 
centrifuged at 16,000 × g for 15 minutes. The supernatant was discarded. Pellets were washed 
twice with 500 µl of PBS. PBS (200 µl) and lysis-binding buffer (800 µl) were added to samples. 
Samples were vortexed for 15 sec and centrifuged for 15 sec at 8000 x g at room temperature.  
 
The supernatant was transferred into high filter tubes and centrifuged for 15 seconds. Diluted 
DNase I (90 µl Dnase incubation buffer mixed with 10µl Dnase 1) was added to each sample, 
followed by 15 min incubations at room temperature. Samples were washed with 500 µl of 
washing buffer and centrifuged for 15 sec at 8000 x g.  The flowthrough was discarded and     
500 µl of buffer II was added, samples were centrifuged and flowthrough was discarded. This 
was done twice. The filter tubes were inserted into sterile 1.5 ml centrifuge tubes. Elution buffer 
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of 20 µl was added to the upper reservoirs of the filter tubes to elute RNA during centrifugation 
at 8000 x g speed. The quantity of RNA was measured using a nano-drop. 
 
2.2.8 cDNA synthesis  
cDNA was synthesised from untreated RNA, transfected siRNA, treated with plant extracts and 
Staurosporine RNA. This was done using Promega reverse-transcription kit. The following 
components were set up in a sterile nuclease free 1.5 ml Eppendorf tube:  2 μl master mix, 3 μl  
Magnesium Chloride (25mM), 2 μl deoxyribonucleotide mix, 2.5 μl oligo-p(dT)15, 1 μl RNase 
inhibitor, 1 μl RNA samples (either untreated and treated cells), 1 μl reverse transcriptase and 
7.5 μl nuclease free water.  Thereafter, the reverse transcription programme was set, using 2700 
(Gene Amp) AB applied biosystem. The samples were placed in the machine and the process of 
the machine was set as follows:  Denaturation of samples at 95 °C for 5 min, incubation at 25 ºC 
for 10 min to allow primers to anneal at mRNA sites, followed by incubation at 42 ºC for an hour 
for cDNA synthesis. After the cDNA synthesis, reverse transcriptase was inactivated by 
incubation at 95 ºC for 10 min and samples were cooled on ice.  
 
2.2.9 Primer design 
Specific primers for the genes of interest (p53, and RBBp6) and a housekeeping gene 
Glyceraldehyde phosphate dehydrogenase (GAPDH) were designed using nucleotide sequences 
from NCBI and primer-plus design software. GAPDH acts as an internal control that is amplified 
together with the cDNA. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is commonly 
used as housekeeping genes and its expression remains constant in the cells or tissues under 
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investigation. In this study it was used to normalise the amount of RNA present in other test 
samples. GADPH is of value in fully characterized systems because it’s used in comparisons of 
gene expression data.  Primers were optimised using PCR to avoid or minimise the formation of 
an artifactual product known as primer-dimers or primer-oligomers. The 3’-terminal sequence of 
the primer molecule is critical for the specificity and sensitivity of PCR. A run of 3 or more G or 
C bases at this position should be avoided since it may stabilize nonspecific annealing of the 
primer.  
 
p53 primers 
Primer F -gttccgagagctgaatgagg 
Primer R-tctgagtcaggcccttctgt 
 
RBBP6 primers 
Primer_F- acagcctagaccctcagcaa 
Primer_R-ctcctggagcgttttcactc 
 
GAPDH primers 
Primer F- ctccccatttatcagctcca 
Primer R-atgcatcgttatgtcgtc 
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2.2.10 PCR  
The PCR process is widely used in a tremendous variety of experimental applications to produce 
high yields of specific DNA target sequences known as cDNA. PCR was used in this experiment 
to observe if designed primers can produce products with high yields, but without primer dimers. 
Primer optimisation was carried out as follows: a cocktail mix containing 10 µl of master mix, 1 
µl of forward and reverse primer, 2 µl MgCl2 and 7 µl of nuclease-free water. The sample was 
carried out, using AB applied biosystem PCR system 2700 (gene amp). Agarose gel 
electrophoresis was used to confirm product formation and if there were no primer dimers.  
 
2.2.11 Quantitative Real Time PCR  
Real-time polymerase chain reaction is a technique based on the polymerase chain reaction. A 
typical workflow of qPCR for gene expression measurement involves RNA isolation, reverse 
transcription, qPCR assay development, qPCR experiment and data analysis. Special attention is 
needed for preventing RNA degradation. For reliable quantification, always include samples for 
standard curves and  measure proper reference genes, of which the expression is constant in your 
experimental conditions, as an endogenous control. 
 
Real-time quantitative polymerase chain reaction (qPCR) differs from normal PCR because of 
the fluorescent reporter molecules in the reaction. The reporter molecule is used to detect and 
simultaneously quantify a specific sequence of p53, RBBp6 and GAPDH in a cDNA sample. 
The amplified cDNA is quantified as it accumulates in the reaction in real time after each 
amplification cycle. Thus, reaction of fluorescent reporter molecules increases proportionally 
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with the increase of DNA amplification in the thermocycler. A specialised thermocycler with 
fluorescence detection modules is necessary for qPCR because it monitors and records the 
fluorescence in real-time as amplification occurs (Pfaffl, 2001; Bustin, 2002). 
 
Experimental procedure 
Preparing qPCR components acquired caution to prevent plasmid DNA contamination. qPCR 
reaction for each sample  was done in duplicates, these are technically replicates required to 
monitor machine error. To minimize variation in pipetting a master mixture containing 
everything except for the template was prepared, and then dispense to individual tubes. The 
templates were added at the final step; the capillary tubes were sealed and covered firmly. all 
liquid was collected at the bottom by brief centrifugation. A typical qPCR reaction tube using 
SYBR Green I chemistry has components in 30 μl of volume as in the following table. Note that 
SYBR green mixture has optimized amount of DNA polymerase, dNTP, reaction buffer and 
dyes. 
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Table 2:1 Preparation of qPCR components for a Real-time PCR reaction 
Components Concentration 
 
Final concentration 
SYBR Green I 
mixture 
 
15 μl  
Primer Forward 10 μM 0.5 μl 
 
Primer Revers 10 μM 0.5 μl 
 
ddH2O  9 μl 
 
cDNA Template  
 
5 μl 
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Table 2:2:Quantitative analysis of cDNA carried out using the Roche lightcycler. The 
parameters on the machine were set as follows: 
Analysis Cycle Segment Temperature (°C) Hold time 
Enzyme activation 1 1 95 2 minutes 
Quantification 40 Amplification 
Denaturation 
Annealing 
Extension 
 
95 
Primer dependent 
72 
 
45 seconds 
45 seconds 
45 seconds 
None 1 Final extension 72 10 minutes 
Melting  1 Melting curve 
Denaturation 
Annealing 
Extension 
 
95 
65 
95 
 
10 seconds 
15 seconds 
0.1°C/Sec 
None 1 Cooling 40 30 seconds 
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Chapter 3 
3 Results 
3.1 Cell viability and cytotoxicity assay 
Cell cytotoxicity is a test tool to measure cell death after treating the cells with extracts of 
Euphorbia mauritanica and Kedrostis hirtella and Staurosporine. The aim of this experiment is 
to reach a net saturation level of 50% cytotoxicity on treated cells. Staurosporine was used as a 
positive control as it induces the desired cytotoxicity. Untreated cells were a point of reference to 
show the effectiveness of the Euphorbia mauritanica and Kedrostis hirtella extracts. 
Cell viability and cytotoxicity percentages of the A549 cell line 
Figure 3:1 Percentage cell death of untreated and treated A549 cells. Samples of cells treated 
with 5 µg/ml of Kedrostis hirtella and Euphorbia mauritanica extracts, and 25 nM Staurosporine 
were taken at different time intervals. 
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After 2 to 4 hrs of treating cells with 5 µg/ml extracts of Euphorbia mauritanica and Kedrostis 
hirtella Figure 3:1 points out an insignificant cell death of 1% to 2%, whereas cells treated with 
Staurosporine exhibit 4% cell death. However, Staurosporine became reactive with a high cell 
death of 20% at 4 hrs. There is no cell death of untreated cells at this point although after 8 hrs 
they show an insignificant cell death of 4%. Cells treated with 5 µg/ml Euphorbia mauritanica 
and Kedrostis hirtella have a constructive response with cell death improved to approximately 
19%. 
 
Evaluating the trend of a positive control (25 nM Staurosporine); extracts demonstrate that, with 
enough time exposure, the target of 50% cell death will be reached. Hence, an estimated 50% 
cell death was achieved at 22 hrs. IC50 is decribed as the half maximal inhibitory concentration 
which is a measure of the effectiveness of a compound in inhibiting biological and biochemical 
function. This quantitative measure indicates how much of a particular drug or substance is 
required to inhibit a given biological process.   Thus, concentration of the extract at 5 µg/ml is 
satisfactory at 22 hrs to cause the desired cell death because the negative control has trivial cell 
death of approximately 7%. On the contrary, at 24 hrs, there is an undesirable cell death of nearly 
60% for cells treated with extracts. Though 25 nM Staurosporine (positive control) maintains the 
approximately accepted 55%, cell death of 15% for untreated cells makes it unacceptable to treat 
cells with 25 nM Staurosporine at 24 hrs.  
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Figure 3:2 Percentage cell death of A549 untreated cells and treated cells.  Samples of cells 
treated with 10 µg/ml of Kedrostis hirtella and Euphorbia mauritanica extracts, and 25 nM 
Staurosporine were taken at different time intervals. 
 
Untreated cells and cells treated with Staurosporine in Figure 3:2 display a line graph similar to 
that of Figure 3:1. Figure 3:2 versus Figure 3:1 illustrates that a higher concentration of 
Euphorbia mauritanica and Kedrostis hirtella extracts (10 µg/ml) has a notable change in cell 
death of nearly 5% at 2 hrs. Figure 3:2 displays gradual increase of about 10% cell death parallel 
to that of Staurosporine (from 2 to 8 hrs) which plateaus after 8 hrs. Rapidly, between 16 hrs to 
22 hrs, cells treated with Euphorbia mauritanica and Kedrostis hirtella extracts show 50% cell 
death at the intersections between Staurosporine and each plant extract. Thus, higher 
concentrations of the extracts reach 50% cell death faster when compared to Figure 3:2. On the 
other hand, Staurosporine reaches 50% at the exact time as Figure 3:1. Cell death percentage 
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after 24 hrs is over 70% and falls out of the desired range for cells treated with 10 µg/ml 
Euphorbia mauritanica and Kedrostis hirtella  
 
Cell viability and cytotoxicity percentages of the Lsqr1 cell line 
Figure 3:3  Cell death percentage of Lsqr1 untreated and treated cells. Samples of cells treated 
with 5 µg/ml of Kedrostis hirtella and Euphorbia mauritanica extracts, and 25 nM Staurosporine 
were taken at different time intervals. 
Figure 3:3 highlights the following: untreated cells have cell death of less than 10% from 2 to 24 
hrs. After 2 hrs, Lsqr1 cells treated with 5 µg/ml Euphorbia mauritanica and Kedrostis hirtella 
extracts show no cell death. After 4 hrs, cells treated with Staurosporine, Euphorbia mauritanica 
and K. hirtellous extracts have a responsive cell death of 17%, 5% and 9%, respectively. Over 8 
hrs to 16 hrs, cells treated with Euphorbia mauritanica and Kedrostis hirtella extracts show a 5% 
increased cell death, whereas cells treated with Staurosporine show a 10% higher cell death. 
After 16 hrs, cells treated with 5 µg/ml Euphorbia mauritanica and Kedrostis hirtella extracts 
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are almost reaching 50% cell death at 24 hrs. However, cells treated with Staurosporine have 
reached 50% cell death at saturation point. Later, at 48 hrs, cells treated with extracts display a 
much higher cell death of over 65%, which falls out of the considered necessary range.  
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Figure 3:4 Percentage cell death of Lsqr1 untreated and treated cells. Samples of cells treated 
with 10µg/ml of Kedrostis hirtella and Euphorbia mauritanica extracts, and 25 nM 
Staurosporine were taken at different time intervals.  
 
Figure 3:4 shows cell death of less than 8% for untreated Lsqr1 cells (from 2 to 24 hrs). Lsqr1 
cells treated with 10 µg/ml of Euphorbia mauritanica and Kedrostis hirtella extracts display cell 
death of 5% at 2 hrs. The cell death percentage of Lsqr1 cells treated with the above extracts 
continues increasing by roughly 5% until 8 hrs.  After 8 to 16 hrs, cells treated with 10 µg/ml of 
Euphorbia mauritanica and Kedrostis hirtella extracts as well as cells treated with 25 nM 
Staurosporine, showed a higher cell death of 10%. Cells treated with 25 nM Staurosporine, 10 
µg/ml of Euphorbia mauritanica and Kedrostis hirtella extracts reached 50%, 55% and 57% cell 
death at 24 hrs, respectively. After 48 hrs, there is an undesirable cell death percentage of over 
68% to 70% in cells treated with 10 µg/ml of Euphorbia mauritanica and Kedrostis hirtella 
extracts.   
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Cell viability and cytotoxicity percentages of normal primary human fibroblast cells 
Figure 3:5 Percentage cell death of normal primary human fibroblast cells treated with                      
5 µg/ml of Euphorbia mauritanica and Kedrostis hirtella extracts. Samples were taken at 
different time intervals to observe cell death.  
 
Figure 3: 5 shows that normal primary human cells are resistant to plant extract. The cell death 
percentage of these normal cells remains constant until 8 hrs and decreases insignificantly at         
16 hrs.  This graph shows no rapid increase in cell death percentage between 8 hrs to 24 hrs.  
Therefore, when normal cells are treated with 5 µg/ml Euphorbia mauritanica and Kedrostis 
hirtella extracts there is insignificant cell death percentage.  
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Figure 3:6 Percentage cell death of normal primary human fibroblast cells treated with                      
10 µg/ml of Kedrostis hirtella and Euphorbia mauritanica extracts. Samples were taken at 
different time intervals to observe cell death.  
 
Figure 3:6 compared to Figure 3:5 exhibit no significant changes in cell death percentage, even if 
the concentration of Kedrostis hirtella and Euphorbia mauritanica extracts is increased to          
10 µg/ml. Therefore, the plant extracts have no significant effect on normal cells. 
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3.2 Apoptosis and necrosis detection using DNA fragmentation gel 
A DNA fragmentation gel electrophoresis is used to test if 50% cell death was by induced by 
5 µg/ml and 10 µg/ml of Euphorbia mauritanica and Kedrostis hirtella on A549 and Lsqr1 cells, 
respectively.  
 
 
 
 
 
 
 
 
 
Figure 3:7 DNA fragmentation gel characterising cells undergoing apoptosis, necrosis or cell 
proliferation when untreated and treated with extracts Euphorbia mauritanica and Kedrostis 
hirtella and Staurosporine.  
 
Lane 1 (Figure 3:7) is a marker that is used to compare bands of the DNA extracted from 
untreated and treated Lsqr1 and A549 cells. Untreated Lsqr1 cells (Lane 3) and A549 cells 
  1      2    3     4    5     6    7        8   9    10   11   12   13  
14  1141414114 15 1) Marker 
3) Untreated Lsqr1 cells for 24 hrs  
4) Lsqr1 cells treated with 10 µg/ml extracts of Euphorbia mauritanica for 24 
hrs 
5) Lsqr1 cells treated with 10 µg/ml extracts Kedrostis hirtella for 24 hrs 
7) A549 cells treated with 25 nM Staurosporine for 22 hrs 
8) Lsqr1 cells treated with 25 nM Staurosporine for 24 hrs 
9) Untreated A459 cells for 22 hrs 
10) A549 cells treated with 5 µg/ml extracts of Euphorbia mauritanica for 22 
hrs  
11) A549 cells treated with 5 µg/ml extracts of Euphorbia mauritanica for 22 
hrs 
12) Untreated A549 cells for 22 hrs 
13) Untreated Lsqr1 cells for 24 hrs 
14) A549 cells treated with 5 µg/ml extracts Kedrostis hirtella for 22 hrs  
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(Lanes 9, 12 and 3) exhibit a single DNA band, thus no necrosis or apoptosis is stimulated. On 
the other hand, smeared DNA (lanes 4 and 5) are observed when Lsqr1 cells are treated for 24 
hrs with 10 µg/ml of Euphorbia mauritanica and Kedrostis hirtella. Yet again, A549 cells 
treated with 5 µg/ml extracts of Euphorbia mauritanica for 22 hrs (lanes 10- 11) show signs of 
smeared DNA. However, A549 cells are treated with 5 µg/ml K hirtella (lane 14) have a 
fragmented DNA.  Fragmented DNA are also observed in lane 7 and 8 when Lsqr1 and A549 
cells are treated with 25 nM of Staurosporine.   
 
 
 
 
 
 
 
 
 
 
 
 
43 
 
3.3 Measuring apoptosis percentages using flow cytometry 
This technique substantiates results obtained from a DNA fragmentation gel electrophoresis as 
well as cell cytotoxicity assay. It quantifies the number of cells and the percentages of viable and 
dead cells that are apoptotic and necrotic. Lsqr1 cells treated with 10 µg/ml and A549 treated 
with 5 µg/ml of Euphorbia mauritanica and Kedrostis hirtella were incubated for 24 hrs and 22 
hrs, respectively. Untreated cells were incubated for 24 hrs for Lsqr1 cells and 22 hrs for A549 
cells.  
 
3.3.1 Cells treated with Kedrostis hirtella 
 
 
 
 
 
Figure 3:8 Cells (A549 on the left and Lsqr1 on the right) treated with Kedrostis hirtella. B1, B2, 
B3 and B4 represent a population percentage of cells that are viable and those undergoing 
necrosis, early, and late apoptosis. 
 
Figure 3:8 show that cells treated with Kedrostis hirtella display a high viable population of 
78.16% for A549 and a required 52.31% of viable Lsqr1 cells. A population of dead A549 cells 
B1=Necrosis                 
B2 = Late 
apoptosis    
B3 =Viable   
B4 = Early 
apoptosis   
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is distributed more on the late apoptosis stage by 4.56% in contrast to necrosis stage. However, 
Lsqr1 cells have a higher population of necrotic cells by 44.10% and a lower 3.09% of dead cells 
for late apoptosis. Therefore, A549 cells treated with Kedrostis hirtella are more apoptotic, 
whereas Lsqr1 is more necrotic.     
 
3.3.2 Cells treated Euphorbia mauritanica  
 
 
 
 
 
Figure 3:9 Graphs displaying cells (A549 on the left and Lsqr1 on the right) treated with 
Euphorbia mauritanica. B1, B2, B3 and B4 represent a population percentage of cells that are 
viable and those undergoing necrosis, early, and late apoptosis. 
 
Cells treated with Euphorbia mauritanica (Figure 3:9) show 68.8% and 58.8% viable population 
for A549 and Lsqr1 cells, respectively. Euphorbia mauritanica extract seems to induce necrosis 
with a cell death percentage of 20.51% for A549 and 30.50% for Lsqr1 cells. However, there is a 
low cell death percentage of about 11.7% for both A549 and Lsqr1 cells at early and late 
B1=Necrosis                 
B2 = Late 
apoptosis    
B3=Viable   
B4= Early 
apoptosis   
 
45 
 
apoptosis. Therefore, treating A549 and Lsqr1 cells with Euphorbia mauritanica largely induces 
necrosis.    
 
3.3.3 Untreated A549 and Lqr1 cells 
 
 
 
 
 
Figure 3:10 untreated A549 (right) and Lqr 1 (left) cells. B1, B2, B3 and B4 represent a 
population percentage of cells that are viable and those undergoing necrosis, early, and late 
apoptosis. 
 
Figure 3:10 shows a mainly viable cell population of 93% for Lsqr1 and A549 untreated. An 
insignificant cell death percentage of 1.15% for A549 and 0.26% for Lsqr1 cells were seen at an 
early stage of apoptosis. A late stage of apoptosis shows 0.77% and 0.13% cell death in A549 
and Lsqr1, respectively, whereas necrotic cells showed an insignificant cell death percentage of 
1.29% for Lsqr1 and 0.05% for A549 cells. 
 
B1=Necrosis                 
B2 = Late 
apoptosis    
B3=Viable   
B4= Early 
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3.3.4 Cells treated with Staurosporine 
 
 
 
 
 
Figure 3:11 A594 cells on the left and Lsqr1 cells on the right treated with 25 nM Staurosporine. 
B1, B2, B3 and B4 represent a population percentage of cells that are viable and those 
undergoing necrosis, early, and late apoptosis. 
 
Cells treated with 25 nM Staurosporine obtained a viable population of about 60.26% Lsqr1 cells 
and 57% A549 cells which resulted in population of 35.09% and 39.64% of A549 and Lsqr1 
cells, respectively, undergoing early apoptosis. However, cells undergoing late apoptosis show a 
low cell death population of 4.11% for A549 cells and 2.77% for Lsqr1 cells. An insignificant 
0.54% and 0.59% population of A549 and Lsqr1 dead cells population point out necrosis. 
Therefore, cells treated with Staurosporine have populations of cells predominating in early 
apoptosis. 
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3.3.5 Normal primary human fibroblast   
 
 
 
 
 
 
 
 
 
 
Figure 3:12  Untreated normal primary human fibroblast cells (top left) and normal primary 
human fibroblast cells treated with 10µg/ml of Kedrostis hirtella (bottom left ) and Euphorbia 
mauritanica (bottom right) extracts for 24 hrs. B1, B2, B3 and B4 represent a population 
percentage of cells that are viable and those undergoing necrosis, early, and late apoptosis 
 
Normal primary human fibroblast cells treated with 10µg/ml of Kedrostis hirtella and Euphorbia 
mauritanica extracts and untreated normal primary human fibroblast cells exhibit more viable 
cells. Therefore plants extracts have an insignificant cell death in normal primary human 
fibroblast cells. 
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3.4 Real-time PCR 
PCR products are quantitated by generating a standard curve relative to a control gene. Real time 
standard curves utilise cDNA and an absolute concentration of each standard is known.  The 
relative quantitation method measures the housekeeping or control genes to normalise expression 
of the target gene. Standard curves were used to quantify the values of unknown concentration of 
target genes expressed in lung cancer cells when treated with plant extracts.  
 
 
 
 
 
 
 
 
 
 
Figure 3:13  The efficiency of GAPDH primers for cDNA amplification were confirmed by a 
standard curve.  GAPDH primers have an efficiency of 1.869 and an error of 0.00309.  
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Figure 3:14 The competence of p53 primers in amplification of cDNA was confirmed by a 
standard curve.  p53 primers had an  efficiency of 1.840 and an error of 0.00313.  
 
 
 
50 
 
 
 
 
 
 
 
 
 
 
 
Figure 3:15  The effectiveness of RBBp6 primers in amplification of cDNA was proven by the 
standard curve. The standard curve efficiency is 1.888, with an error of 0.0681.  
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Figure 3:16 The expression comparison of RBBp6 and p53 cDNA for untreated Lsqr1 cells, 
including cells treated with 10 µg/ ml of the plant extract. 
 
Figure 3:16 shows 0.9 p53 expression fold of Lsqr1 cells treated with Euphorbia mauritanica 
and untreated Lsqr1 cells treated with Kedrostis hirtella have a is slightly higher by 0.1 fold. On 
the other hand, RBBp6 expression is the same within 0.8 fold for Lsqr1 cells treated with 
Euphorbia mauritanica and Kedrostis hirtella, and untreated Lsqr1 cells. Moreover, observation 
of p53 expression versus RBBp6 expression shows 0.1 fold expression ratio difference for Lsqr1 
untreated cells; this is equivalent to Lqr cells treated with E. mauritanica. However, Lsqr1 cells 
treated with Kedrostis hirtella have a p53 expression level that is slightly higher by 0.2 fold, 
compared to RBBp6 expression level. Therefore, Kedrostis hirtella has an effect on p53 
expression and no effect on RBBp6 expression when compared to untreated Lsqr1 cells. On the 
other hand, Euphorbia mauritanica has no effect on the expression of p53 and RBBp6 when 
weighed against untreated Lsqr1 cells. 
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Figure 3:17: The expression comparison of RBBp6 and p53 cDNA in untreated A549  cells 
including those treated with 5 µg/ ml of the plant extract. 
 
Figure 3:17, Untreated A549 cells show a high RBBp6 expression of 0.985 and a lower p53 
expression of 0.83 when compared to other treated A549 cells. The expression of RBBp6 is 
reduced to 0.9 and 0.8 for A549 cells treated with Euphorbia mauritanica and Kedrostis hirtella, 
respectively. However, p53 expression has increased to 0.9 for A549 cells treated with 
Euphorbia mauritanica and Kedrostis hirtella. Therefore, plant extracts have an insignificant 
change in the expression of RBBp6 and p53 in A549 
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Chapter 4 
4 Discussion  
4.1 Introduction 
The elucidation of molecular and cellular targets critical in cancer development and prevention is 
an area of intensive research and is driving the development of novel small-molecule 
compounds, which may prevent carcinogenesis, curtail its progression, or even cure the disease. 
On the other hand, in spite of significant advances over the last half century in our understanding 
of the genesis of lung cancer and the application of targeted drug therapy, lung cancer remains 
the leading cause of cancer deaths among men and the second leading cause of cancer deaths 
among women. New chemopreventative and chemotherapeutic approaches to the prevention and 
treatment of lung cancer are needed to reduce  mortality since many patients with advanced lung 
cancer fail to respond to current treatment regimens. In this study we illustrate the use of two 
natural plant extracts as potential target. 
 
4.2 Cell cytotoxicity 
Cell viability and cytotoxicity assays are used for drug screening and cytotoxicity test of 
different chemical compound. In this study we used the MTT assay as our assay of choice to 
determine cell growth or inhibition activity of cancer cells aftertreatment with  plant extracts are 
used as anticancer compounds (Cardellina et al., 1993). Previous studies used the MTT assay to 
measure significant variations in the inhibition activity when multi-drugs were tested on 
leukaemia cell lines. Thus, it was rated the most accurate assay amongst other cell viability 
assays (Marks et al., 1992). It has no limitations for testing more than variables such as drug 
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concentration, time of exposure to drug, length of assay, and cell density (Mosmann, 1983). 
MTT was used to measure 50% cell growth or inhibition induced by Euphorbia mauritanica and 
Kedrostis hirtella extracts on A549 cells and Lsqr1 cells.  Untreated cells were used as control 
and cells treated with Staurosporine as a positive control. Figure 3:1-3:4 showed that A549 and 
Lsqr1 untreated cells had a trivial cell death. Thus, uncontrolled factors such as natural death or 
lack of nutrients are not the cause of attaining 50% cell death when cells are treated with the 
extracts. Therefore, this data is reliable.  
 
The A549 cell line treated with 5 µg/ml of Euphorbia mauritanica and Kedrostis hirtella extracts 
attained 55%-56% growth inhibition at 22 hrs (Figure 3:1). The concentration of the extracts in 
Figure 3:2 was further increased to 10 µg/ml for Euphorbia mauritanica and Kedrostis hirtella. 
Inhibition of 50% growth was reached after short time exposure, between 16 to 22 hrs. 
Therefore, extracts showed a significant reduction of A549 cell growth in a dose and time-
dependent manner. Similarly, Lsqr1 cells exhibit cell growth inhibition properties that are 
dependent on the dosage of the extracts and exposure time. Lsqr1 cells treated with 5 µg/ml 
Euphorbia mauritanica and Kedrostis hirtella extracts reached approximately 49% inhibition at 
24 hrs. However, a high dose of 10 µg/ml Euphorbia mauritanica and Kedrostis hirtella extracts 
resulted in a 50-51% growth inhibition at 24 hrs incubation time (Figure 3:4). These results are 
similar to that of Creemers et al. (1996); in which they showed antitumour activity against 
colorectal and ovarian cancer tested with Nyssacea Camptotheca accuminata extracts. They 
further discovered that compounds such as Irinotecan and topotecan derived from Nyssacea 
Camptotheca accuminata are the main stimulates of antitumor activity against colorectal and 
ovarian cancer (Creemers et al., 1996). However, Kummalue et al. (2010) compared inhibition 
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of two lung cancer cell lines and a breast cancer cell line when treated with extracts and they 
observed a significant growth inhibition in the dosage dependent manner, but only in the A549 
cell line treated with 2.597 μg/ml Sapindus rarax water extract. Hence, the extract contains 
compounds, which inhibit human tumour cell growth. Thus, Euphorbia mauritanica and 
Kedrostis hirtella extracts might contain a wide range of compounds that induce antitumour 
activity at certain dosages with time. For example, phenolic compounds of Terminalia chebula 
show an inhibition of growth in human (MCF-7) and mouse (S115) breast cancer cell lines, a 
human osteosarcoma cell line (HOS-1), a human prostate cancer cell line (PC-3) and a non-
tumorigenic, immortalized human prostate cell line (PNT1A) (Saleem et al., 2002).  
 
In addition, compounds derived from plant extracts are not the only ones with anti-proliferative 
activity. Compounds isolated from bacteria also exhibit anti-proliferative activity e.g. 
Staurosporine used as a positive control in this study. Staurosporine is compound isolated from 
Streptomyces stauroscopes bacterium and capable of  inducing apoptosis (Omura et al., 1977, 
Chae et al., 2000) and results obtained (Figure 3:1-3:4) in this study shows that Staurosporine 
continue to induce cancer cell death in an apoptotic manner.  
 
Previous studies have shown that Staurosporine decreases phosphorylation of pRB, meaning that 
it directly inhibits protein kinases that are important for phosphorylation of pRB (Bruno et al., 
1992). Inhibition of protein kinases promotes pRB-E2F association and dephosphorylation of 
pRB, which induces apoptosis and inhibits the progression of cancer cells (Hickman, 2002, Chae 
et al., 2000). Therefore, Staurosporine is effective as a positive reference when considering 
previously studies (Bruno et al., 1992). If they were to be considered for treatment against lung 
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cancer, plant extracts used in this experiment were expected to behave in a similar manner as 
Staurosporine, but they increase cell death with time exposure. This means that at high dosages 
there might be a possibility that the extracts may result in normal cells cytotoxicity. Therefore, 
investigation such as flow cytometry, DNA fragmentation and gene expression are needed to 
gain insight information into the mechanism of action these extract employ. 
 
4.3 DNA fragmentation 
DNA fragmentation  is a key feature of programmed cell death and also occurs in certain stages 
of necrosis.  Apoptosis is characterized by the activation of endogenous endonucleases with 
subsequent cleavage of chromatin DNA into internucleosomal fragments of 180BP.  In this study 
we have used DNA fragmentation assay to determine whether cells treated with Euphorbia 
mauritanica and Kedrostis hirtella extracts have anti-proliferating effects. 
 
A pattern of laddering is characteristically commonly associated with the apoptotic process, but 
not with other modes of cell death, like necrosis which is represented by a smeared DNA band 
pattern (Zhivotosky  et al., 1999). Untreated Lsqr1 and A549 cell lines were used as controls and 
produced genomic DNA features of a single band as an indication of no cell death. These results 
are in line with several other reported lack of DNA fragmentation in both the untreated cancer 
cells and treated normal cells with are always selected as control (Zhivotosky et al., 1999).   
 
Euphorbia mauritanica and Kedrostis hirtella extracts were used to treat Lsqr1 and A549 cells.  
Smeared DNA wells were observed when Lsqr1 cells were treated for 24 hrs with 10 µg/ml of 
Euphorbia mauritanica and Kedrostis hirtella, and A549 cells are treated with 5 µg/ml extracts 
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of Euphorbia mauritanica for 22 hrs. These results were similar to those observed by 
Chowdhury et al, 2009 inwhich they also observed a smearing DNA profiling after treating  
HeLa cells with some plant extract. It was observed that even though plant extracts failed to 
induce DNA fragmentation in HeLa cells, they were able to induce cell death, which meant that 
some toxic chemicals or compounds could induce cell death without DNA fragmentation 
(Chowdhury et al., 2009). Smeared DNA might suggest that necrosis took place resulting in 
random digestion of the DNA (Wiliams et al., 1974). 
 
In this study using A549 cells treated with 5 µg/ml Kedrostis hirtella, we were able to observe a 
weak signal of nucleosomal DNA fragments. Similarly, Zhivotosky and Orrenius (2001) studies 
demonstrates pattern of laddering DNA, which was observed only in the treated samples. This 
suggests that plant extracts can induce apoptotic cells as result lead to oligonucleosomal DNA 
degradation. When cells were treated with Staurosporine a fragmented DNA pattern similar to 
that of a DNA ladder was observed on the gel. This clearly demonstrated that Staurosporine 
induced apoptosis as detected by apoptosis because of characteristics such as chromatin 
condensation and DNA fragmentation (Williamson et al., 1970; Skalka et al., 1976)  
 
Belmokhtar et al (2001) performed a study on Staurosporine and discovered that it has a 
possibility of inducing at least two different signalling pathways of cell death. Their results 
correspond with findings of McCarthy et al. (1997), which proposed that apoptosis is triggered 
by an enzyme that requires a nuclear event. Hence, they were able to activate two unrelated 
endonucleases responsible for DNA fragmentation. Thus, DNA fragmentation of Lsqr1 and 
A549 cells treated with Staurosporine was in line with that by McCarthy et al., (1997). In order 
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to verify percentage apoptosis, Flow cytometry studies was applied to confirm if cell death was 
by way of apoptosis or necrosis.  
  
4.4 Flow cytometry 
Graphs of cytogram dot plots represent two measurement parameters, on the x- and y-axes. The 
x-axis of cytochrome dot plots displays FL1-FITC detection and the y axis represents FL2-PI. 
The FITC signal detector (FL1 channel) is used for measuring Annexin-V-FITC binding and the 
phycoerythrin signal detector (FL2 channel) measures PI staining (Nicoletti et al., 1991; Lyons 
et al., 1992; Lecoeur, 2001). For this purpose, the cytogram graphs show a labelling pattern of 
cell count height on a density gradient, which is represented in dots. Dot density fraction of the 
cells is interpreted as follows: a fraction of the cells dots on B3 are viable cells which are 
negative for both PI and Annexin-V. Untreated cells are most likely to have a higher viable 
population as a result of not binding to PI and Annexin-V (Gougen, 1997; Lecoeur, 2002). 
Untreated Lsqr1 and A549 show a 90% viable population. While those treated with 
Staurosporine and extracts presented 50% cell viability. These results confirmed our earlier 
results obtained in the cell cytotoxicity assay (Figure 3.1-3.6).   
 
Mostly because cells treated with Staurosporine undergo apoptosis, they are likely to  be 
distributed between  B2 (late apoptosis) and the B4 (early apoptosis) stage (Bunch et al., 1992; 
Gester, 1998). Staurosporine induces cell death predominately in early apoptosis, but reduced 
population of dead cells in late apoptosis. The density dots population on B4 of the cytogram 
represent early apoptotic cells that are PI negative and Annexin-V positive (Nicoletti et al., 1991; 
Lyons et al., 1992). The late apoptotic cells in B2 are PI positive and Annexin-V positive 
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(figure). This data suggests that Staurosporine is involved in the induction of early apoptosis 
events. Previous studies suggested that Staurosporine triggers both the p53-independent and 
dependent apoptotic pathways (Lin et al., 1999, Chen et al., 1999, Belmokhtar et al., 2001). 
Apoptosis specific caspase-3 cleavage products can be measured in blood of a patient receiving 
cytotoxic treatment. This can serve as a specific marker to detect improvement of a cancer 
patient under therapy.  
 
A549 cells and Lqr1 cells treated with Euphorbia mauritanica and Kedrostis hirtella extracts 
resulted in predominantly necrotic cells (Figure 3.8-3.9).  Plant extracts produce toxins that 
affect the external of the cell causing a disruption in the cell membrane leading to necrosis 
(Edinger et al., 2004; Zong et al., 2006). Necrosis is an unregulated process that disrupts the 
plasma membrane leading to the spillage of intracellular protein. The spillage of intracellular 
protein enhances or activates the host immune response to remove dead cells by tissue 
macrophages (Buzzai et al., 2005, Olofsson et al., 2007). However, necrotic cells are internalized 
by macropinocytotic mechanism. Hence, a part of these cells can be engulfed by phagocyte 
whereas other dead cells become localized in a certain area causing a build-up that leads to local 
inflammation (Edinger et al., 2004; Krysto et al., 2006).  Furthermore, if therapeutic drugs or 
remedies result in necrosis, it becomes difficult to check if the patient is responding well to 
treatment.  Necrosis has a very few specific methods of detection (Buzzai et al., 2005, Olofsson 
et al., 2007). 
 
However, in Figure 3.8 there is some evidence of late apoptosis in the case of A549 cells treated 
with 5 µg/ml of Kedrostis hirtella. In a study by Chinkwo, (2005) on the Sutherlandia frutescens 
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extract they confirmed that there are few compounds in the extracts that have anti-cancer 
properties that are well considered to activate the central death caspase-3.Euphorbia mauritanica 
and Kedrostis hirtella extracts might have compound which activate apoptosis.  Therefore, gene 
expression of p53 (pro-apoptotic) and RBBp6 (pro-proliferation) were studied to check if there 
might be compound in the extracts that could inhibit or stimulate the expression of the two genes 
as they antagonise each other and play a role in both cell survival or cell death.  
 
4.5 Real-time PCR 
In most cases, cancer cells show overexpression of RBBp6 and has been characterised by 
mutations or malfunctioning of p53 (Motadi et al., 2011).  However, in normal cells p53, RBBp6 
and Mdm2 expressions are controlled at moderate level, but during cellular stress and oncogenic 
warnings, p53 is highly expressed. Cellular stresses stimulate apoptosis and deactivate cell 
growth, but once the problem has been resolved, p53 levels are reduced via Mdm2/ RBBp6 
mediated ubiquitination. Mdm2 is a cellular antagonist of p53 and acts to limit the p53 
expression and suppresses its function in unstressed cells (Gao and Scott, 2003; Moll and 
Petrenko, 2003, Yoshitake et al., 2004). Mdm2 has a short lifespan, thus it will not eradicate p53 
completely.  As a result, p53 can continue with function in normal cells.  
 
Cancer cells, however, cannot undergo cell cycle because it is not controlled and there will be 
abnormal growth of defective cells.  Thus, there are drugs that prevent the interaction between 
Mdm2 and tumour suppressor protein (RB and p53).  In so doing, programmed cell death is 
enhanced (Moll and Petrenko, 2003). Now, the question is: how do drugs targeted for RBBp6 in 
cancer cells inhibit the function of p53 degradation. RBBp6 arise from p53-associated cellular 
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protein (PACT) family and has conserved N-terminal which facilitates in regulation of RB and 
p53 (Yoshitake et al. 2004; Li et al., 2007). However, RBBp6 enhances cell growth in cancer 
cells and normal cells. RBBp6 has p53 and Rb binding sites, but little is known about preventing 
an interaction between RBBp6 and tumour suppressor proteins (Rb and p53).  
 
Studies show that a higher expression of RBBp6 is associated with poor prognosis and is useful 
for predicting the outcome of a cancer patient after surgery or treatment (Gao and Scott, 
2003;Yoshitake et al., 2004; Motadi et al., 2011). If RBBp6 is down regulated, the expression of 
p53 increases whereas p53 silencing results in RBBp6 accumulation (Motadi et al., 2011). Lsqr1 
and A549 cells were treated with Euphorbia mauritanica and Kedrostis hirtella extracts 
illustrated no significant effect in RBBp6 level expression. 
  
4.6 Conclusion  
Although, plant extracts are not significantly affecting the RBBp6 expression level, they areused 
for anti-cancer therapy, because they do not have an effect on normal cells and they induce 
necrosis and late apoptosis in lung cancer cells. However, further studies have to be done to 
illustrate how these plant extract are inducing late apoptosis and necrosis in lung cancer cells.  
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4.7 Future recommendation 
Further studies such as Detection Fluorescence Microscopy should be done to verify results 
obtained from flow cytometry and detect cell morphology in treated lung cancer cells. RBBp6 
and p53 protein expression level have to be checked using western blot. 
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